We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of BIOTW yet.

BIOTW Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q1 2023, worth a combined $0 — down 100% from $3.83M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of BIOTW and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $2.05M sold.

  • 0 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q1 2023, down from 48 in Q4 2022.
  • Funds reported $0 of Biotech Acquisition Company Warrant stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Biotech Acquisition Company Warrant positions in Q1 2023 and 47 closed out, a net change of -47 holders.
  • The largest Biotech Acquisition Company Warrant seller in Q1 2023 was Radcliffe Capital Management, an estimated $2.05M sold.

Based on aggregated 13F filings for Q1 2023.